

EVALUATION OF THE CLASSICAL COMPLEMENT PATHWAY IN ACTIVATION OF RHEUMATOID ARTHRITIS

Thesis

Submitted for partial fulfillment of MD Degree in Rheumatology & Rehabilitation

By

Marwa Salah El Sayed Shabana

MB, B.Ch, McSc

Supervised by

Prof. Dr. Samia Mohamad Hassan Fadda

Professor of Rheumatology & Rehabilitation

Faculty of medicine, Cairo University

Prof. Dr. Azza Ahmed Aboul Enein

Professor of Clinical Pathology

Faculty of medicine, Cairo University

Dr. Hanan El sayed Ali Darweesh

Assistant Professor of Rheumatology & Rehabilitation

Faculty of Medicine , Cairo University

Faculty of Medicine

Cairo University

2014

Acknowledgement

First and foremost, thanks to "**ALLAH**" to whom I relate any success in achieving any work in my life.

Special thanks to **Prof. Dr. Samia Mohamad Fadda** Professor of Rheumatology and Rehabilitation ,Faculty of Medicine ,Cairo University, to who I owe many valuable remarks and a lot of precious time and effort, her guidance and kind assistance supported in completing this work.

I am deeply indebted to the great help offered by **Prof. Dr. Azza Ahmed Aboul Enein** , Professor of Clinical Pathology & chemical pathology, Faculty of Medicine, Cairo University, for her kind help in preparing and supporting this work.

My words stand short of my supreme gratitude and thanks to **Dr. Hanan Elsayed Ali Darweesh** Assistant Professor of Rheumatology and Rehabilitation, Faculty of Medicine, Cairo University, for her continuous supervision, valuable guidance, generous encouragement, help and overall her moral support and kindness that gave me and this work a lift to the scope of light.

Finally, I wish to thank all members of my family especially my parents who taught me what medicine means and gave me continuous

help, encouragement and support and to my husband & his parents for their support.

Abstract

Background: Complement activation has been implicated in the pathogenesis of RA. C1q–C4 complexes are a specific parameter of classical pathway activation.

Objective: we aimed to investigate plasma levels of complement parameter; C1q & activated C4 in Rheumatoid arthritis, and also to assess their association with disease activity.

Methods: 50 RA patients classified into inactive RA group whose DAS 28 <2.6 (n=23/50) and active group had DAS 28 \geq 2.6 (n =27/50) and control group (n=20). RA patients were submitted to full history taking, full clinical examination, routine laboratory investigations, assessment of disease activity. C1q antibodies and C4d antibodies were measured using Enzyme-Linked Immunosorbent Assay (ELISA) technique.

Results: The median plasma levels of C1q and C4d in RA patients (9.3, 8.7 ug/ml, respectively) was statistically significant higher than the control group (2.4 and 4.8 ugEq/ml, respectively) (P=0.01, 0.001 respectively). Active RA patients had elevated levels of C1q and C4d comparing to those with inactive disease. RA patients with elevated median levels of C1q & C4d had higher statistically significant difference than those with normal levels regarding duration of morning stiffness, VAS, 28 TJC, 28 SJC, DAS28, ESR and CRP. There was a significant positive correlation between the median of C1q and C4d levels in our RA patients ($r= 0.39$, $P = 0.004$). Also these complement parameters had positive correlation with duration of morning stiffness ($r= 0.539, 0.275$, $P = 0.001, 0.05$, respectively), VAS ($r=0.461, 0.335, P=0.001, 0.017$), DAS-28 ($r = 0.523, 0.393$; $P=0.001$), ESR ($r = 0.561, 0.454$; $P= 0.001$) and CRP ($r =0.492, 0.411$; $P= 0.001$).

Conclusion: we can conclude that the classical complement pathway activation is correlated with disease activity in RA patients, supporting this assumption C1q and C4d levels were found to be significantly correlated with disease activity parameters.

Key words: rheumatoid arthritis, disease activity parameters, classical complement pathway, C1q, C4d.

Table of contents

		Page
Acknowledgment		
Abstract		
List of abbreviations		I
List of table		v
List of figures		vii
Introduction &aim of work		1
Review of Literature	Chapter (1)	3
	Chapter (2)	28
	Chapter(3)	52
Patients &Methods		67
Results		79
Discussion		102
Summary &Conclusion		113
Recommendation		116
References		117
الملخص العربي		١

List of Abbreviations

ACPA	Anti-citrullinated protein antibodies
ACR	American College of Rheumatology
ADAMTS	A Disintegrin and metalloproteinase with thrombospondin motif
ANCA	Anti-neutrophil cytoplasmic antibody
ANOVA	ANalysis Of VAriance
APCs	Antigen-presenting cells
ATP	Adenosine triphosphate
C`	Complement
CCL	Chemokine (C-C motif) ligand
CD28	Cluster of Differentiation 28
CH50	Complement hemolytic
CIA	Collagen-induced arthritis
CRP	C-reactive protein
CTLs	Cytotoxic T cells
CTLA4	Cytotoxic T cell-associated antigen 4
CXCL13	Chemokine (C-X-C Motif) Ligand 13
DAF	Decay-accelerating factor
DAS-28	Disease activity score in 28 joints
DC	Dendritic cells
EA	Sheep erythrocytes
EBV	Epstein-Barr virus
E-C4d	Erythrocyte-bound C4d
ECs	Endothelial cells
EDTA	Ethylene diamine tetraacetic acid

EGF	Epidermal growth factor
EGTA	Ethylene glycol tetraacetic acid
ELISA	The enzyme-linked immunosorbent assay
EULAR	The European League Against Rheumatism
FADD	Fas-associated via death domain
Fc	Fragment crystallizable
FcγR	The Fc receptors for IgG
FD	Factor D
FLIP	FLICE-like inhibitory protein
FLSs	Fibroblast-like synoviocytes
GH	General health
GM-CSF	Granulocyte–macrophage colony-stimulating factor
GpE	Guinea pig erythrocytes
HLA	Human leukocyte antigen
HLA-DRB1	Human leukocyte antigen, class II, DR beta 1
HUVS	Hypocomplementemic urticarial vasculitis syndrome
IFN-γ	Interferon-γ
Ig G Fc	Immunoglobulin G ,Fragment, crystallizable
IL-1Ra	IL-1 receptor antagonist
IL	Interleukin
LT-β	Lymphotoxin- β
MAC	Membrane attack complex
MAps	MBL-associated proteins
MASP	Mannan-associated serine protease
MBL	Mannan-binding lectin

MHC	Major histocompatibility complex
MMP	Matrix metalloproteinases
Murin BM-DC	Murine bone marrow-derived DCs
NK	Natural killer cells
OPG	Osteoprotegerin
OR	Odds ratio
PADI4	Peptidyl arginine deiminase 4
PBS	Phosphate buffered saline
PDGF	Platelet-derived growth factor
PTPN-22	Protein tyrosine phosphatase, non-receptor type- 22
RA	Rheumatoid Arthritis
RANKL	Receptor Activator for Nuclear Factor κ B Ligand
RbE	Rabbit erythrocytes
SAP	Serum amyloid P
SCR-p	Short consensus repeats protein
SE	Shared-epitope
SERPINS	Serine proteinase inhibitors
SLEDAI	Systemic Lupus Erythematosus Disease Activity Index
SNPs	Single-nucleotide polymorphisms serine proteinase inhibitors
SPSS	Statistical Package for the Social Sciences
T reg cells	Regulatory T cells
TCC	Terminal complement complex
TCR	T cell receptor
TGF- β	Transforming growth factor- β
TIE2	Tyrosine kinase with immunoglobulin-like loops

TIMP	Tissue inhibitor of metalloproteinase
Th	T helper
TNF- α	Tumor-necrosis factor- α
Tr cells	suppressor T cells
TRAIL	TNF-related apoptosis inducing ligand
TRIFMA	Time-resolved immunofluorometric assay
VAS	Visual analogue scale
VEGF	Vascular endothelial growth factor
VLA	Very late activation antigen
WBCs	White blood cells
28 SJs	28 swollen joints count
28 TJs	28 tender joints count

List of tables

Table No.		Page
Table 1	*Components of the Complement Activation Cascades.	39
Table 2	*Complement Regulatory Proteins.	40
Table3	* Complement Receptors	41
Table 4	* Involvement of C1q in various cellular functions	62
Table 5	*Twenty-eight-joint counts	72
Table 6	*Demographic data of all Rheumatoid Arthritis patients	79
Table 7	*Demographic data of control group	80
Table 8	*Laboratory data of control group.	80
Table 9	*Clinical data of Rheumatoid Arthritis patients	81
Table 10	*Laboratory data of Rheumatoid Arthritis patients	82
Table 11	*Cumulative dose of drug used in RA patients.	83
Table 12	*Comparison between RA and control groups as regards C1q and C4d.	84
Table13	*Comparison between RA patients with normal C1q level and those with elevated C1q level regarding the clinical data.	85
<u>Continued</u>		
Table 14	*Comparison between RA patients with normal C1q level and those with elevated level regarding laboratory data.	86

Table 15	*Comparison between RA patients with normal level of C4d and those with elevated level regarding some clinical data	87
Table 16	*Comparison between of RA patients with normal level of C4d and those with elevated level regarding the laboratory data	88
Table 17	*Comparison between active & inactive RA patients and control regarding C1q&C4d.	89
Table 18	*Comparison between both sexes as regard clinical and laboratory data.	91
Table 19	*Correlation between C1q and clinical parameters.	93
Table 20	*Correlation between C4d and clinical parameters.	94
Table 21	*Correlation between C1q, C4d and cumulative doses of medications in RA patients	98
Table 22	*Correlation of C1q and C4d with some investigation parameters in RA patients	99

List of figures

Figures no.		Page
Figure 1	Hypothetical model of Rheumatoid Arthritis causation	5
Figure 2	Pathogenesis of Rheumatoid Arthritis	17
Figure 3	The three pathways of complement activation	30
Figure 4	The first protein in the classical pathway of complement activation is C1, which is a complex of C1q, C1r, and C1s	31
Figure 5	Schematic form of the classical pathway of complement activation	32
Figure 6	Classical and alternative pathways	34
Figure 7	The terminal sequence	38
Figure 8	A simplified scheme of Structure of C1q	62
Figure 9	Scheme for C4 cleavage	66
Figure 10	Mannequin format used to record tenderness and swelling	73
Figure 11	Frequency of treatment used as combination	83
Figure 12	Comparison between the median levels of C1q and C4d in RA and control groups	84
Figure 13	Comparison between median C1q in different groups.	89
Figure 14	Comparison between medians of C4d in different groups	90
Figure 15	Positive correlation between C1q and C4d	92
Figure 16	Correlation between C1q and duration of morning stiffness	95
Figure 17	Correlation between C1q and visual analogue scale	95
Figure 18	Correlation between C1q and DAS28	96
Figure 19	Correlation between C4d and duration of morning stiffness	96
Figure 20	Correlation between C4d and VAS	97
Figure 21	Correlation between C4d and DAS-28	97
Figure 22	Correlation between C1q and ESR (mm/hr)	100
Figure 23	Correlation between C1q and CRP (mg/L).	100
Figure 24	Correlation between C4d and ESR (mm/hr)	101
Figure 25	Correlation between C4d and CRP (mg/L)	101

Introduction

Rheumatoid arthritis (RA) is an inflammatory autoimmune disease characterized by chronic inflammation of the joints; eventually leading to bone and cartilage destruction. Complement activation has been implicated in the pathogenesis of the disease. Various studies identify complement activation as a main event in the inflammatory cascade in RA (*Makinde et al., 1989 and Hietala et al., 2004*).

Involvement of complement in the pathogenesis of RA was also confirmed in experimental studies. Collagen-induced arthritis (CIA), an experimental animal model for human RA, was induced in C3- and factor B-deficient mice. In complement-deficient mice, arthritis was reduced or completely absent, whereas normal mice were susceptible to CIA, indicating an important role of complement in the induction of disease (*Hietala et al., 2002*).

The complement system is one of the major effector mechanisms of the innate immune system and it plays an important role in immune defence. The biological functions of complement are opsonization and phagocytosis, stimulation of inflammatory reactions (*Abbas et al., 2000*).

The complement system is formed by an enzymatic cascade composed of plasma proteins that, once stimulated, can achieve tremendous amplification and effectively fight the invading microorganisms. Under certain conditions, a pathological immune reaction may develop against complement components, which on one hand reflects an underlying

autoimmune process and may lead to inflammation and tissue injury. (*Potlukova and Kralikova, 2008*).

C1q, C4 complexes are a specific parameter of classical pathway activation; increased plasma levels of these complexes in RA indicate involvement of the classical pathway of complement in RA (*Wouters et al., 2006*).

Levels of the acute-phase protein, C-reactive protein (CRP), are elevated in the majority of patients with RA and are associated with disease activity. CRP bound to a ligand can activate complement, and there is evidence that CRP-mediated activation of complement occurs in RA. Both immune complexes and ligand-bound CRP activate complement via the classical pathway (*Romero et al., 1998 and Molenaar et al., 2001*).

Aim of work

This study will be performed to investigate plasma levels of complement parameter, and also to assess the association of these parameters with disease activity.

Rheumatoid Arthritis

Introduction

The disease that is currently clinically recognized as rheumatoid arthritis (RA) was first defined by Sir Alfred Baring Garrod in 1859, when he differentiated it from gout, which we now know is caused by crystals of monosodium urate. In the 1870s, there was uncertainty among physicians whether acute rheumatism (rheumatic fever, RF) and chronic rheumatism (rheumatoid arthritis, RA) were separate diseases or that there was one “rheumatism” whose manifestations differed due to influences of age, heredity, and environment (*Klareskog et al.,2006*).

Rheumatoid arthritis is a systemic autoimmune disease which is characterized by chronic inflammation of the joints resulting in joint destruction. Patients experience chronic pain and suffering, functional impairment, increasing disability, without treatment there is a reduction in life expectancy. The availability of effective therapies makes it imperative to identify patients early so that control of inflammation can prevent joint destruction and disability (*Mody and Cardiel, 2008*).

RA has a significant impact on health-related quality of life; it is associated with increased health-care costs and an increased mortality when affected patients are compared with the general population (*Sihvonen et al., 2004*).

Epidemiology

The incidence of RA varies across populations. Estimates from North America and Northern Europe range from 20 to 50 cases per 100,000